The Top Three Nuclear Energy Stocks to Buy Right Now

Cameco produced 15% of global uranium in 2025 and reported revenue +11% and EPS +114% year-over-year, with a net margin of 16.93% and a debt-to-equity of 0.14. Constellation operates 21 U.S. reactors, saw revenue +8.34% in 2025, net margin 9.1%, D/E ~0.61, and pays a 0.57% dividend yield with a 21% payout ratio. BWX Technologies, leveraging naval reactor experience to pursue factory-built small modular reactors, reported revenue +18% and EPS +20% in 2025; all three firms are presented as long-duration thematic plays on a global nuclear renaissance driven by DOE targets, AI power demand, and supply-side dynamics.

Analysis

Cameco is the most levered, durable play on a structural tightening in the nuclear fuel cycle; beyond headline production share, the second-order choke points are conversion/enrichment capacity and long lead times for new mine restarts. Those bottlenecks create a multi-year mismatch between demand coming from new reactor builds/PPAs and incremental supply, giving producers with high-grade assets and flexible contracting the ability to reprice off-take windows and extend margins without immediate capex.

BWXT is a binary, technology-and-regulation story: its naval business provides a steady base and scale advantages in reactor components, but commercial SMR economics hinge on serial factory fabrication, supply-chain scale (forgings, modular steel, qualified welders) and multi-jurisdictional NRC/IAEA licensing—expect 3–7 years before material civil revenue. That timeline makes BWXT more an event-driven option than a cash-flow compounder; any delay inflates build costs and stretches payback for off-takers (data centers, remote bases).

Constellation offers lower volatility exposure to the same secular demand (AI + baseload electrification) with clearer cash flow and contracting leverage; its rerating will be incremental — driven by PPAs and successful plant restarts — rather than binary technological outcomes. The consensus underweights physical inventory dynamics and overweights SMR near-term commercialization: structurally tight uranium + slow supply response favors upstream names now, while SMR beneficiaries deserve option-like sizing until repeatable factory economics are demonstrated.

Key Decisions for Investors

• Long CCJ (12–36 months): Buy shares or 18–24 month LEAP calls to capture secular rerating from uranium tightness and Westinghouse JV optionality. Size as 2–4% of portfolio, set a tactical stop at -30% or hedge with 1y 25% OTM puts. R/R: asymmetric — limited corporate leverage vs potential 50–100% rerate if spot/pricing rebalances and contracting accelerates.
• Long CEG (6–18 months): Buy shares or 9–12 month calls to play stable cash flows and PPA wins for AI/data-center demand. Target modest upside (20–40%) with low volatility; use 6–12 month protective puts if financing markets weaken (rates spike) to limit drawdown.
• Event-driven BWXT options (24–48 months): Buy a defined-risk LEAP call spread (e.g., buy 01/2028 LEAP call / sell higher strike to offset premium) to capture commercialization upside on NRC milestones or first commercial module orders. Keep position as a small option-sized bet (<=1% portfolio) due to binary execution risk; alternatively sell short-dated implied volatility if you expect licensing delays.
• Macro hedge / beneficiary: Long MSFT (12–24 months) — buy calls or shares to capture downstream demand from data-center PPAs and long-term offtake agreements with utilities. Use this as a diversified play on AI-driven baseload demand; trim into any sharp rallies tied to regulatory approvals or large PPA announcements.